 |
|
|
Publications
Neutralization of granulocyte
macrophage colony-stimulating factor decreases amyloid beta 1-42 and
suppresses microglial activity in a transgenic mouse model of Alzheimer's
disease.
Manczak M, Mao P, Nakamura K, Bebbington C, Park B, Reddy PH. Hum Mol
Genet, October 2009; 18(20):3876-93. Epub 2009 Jul 19.
Granulocyte-macrophage
colony-stimulating factor antibody suppresses microglial activity:
implications for anti-inflammatory effects in Alzheimer's disease and
multiple sclerosis.
Reddy PH, Manczak M, Zhao W, Nakamura K, Bebbington C, Yarranton G, Mao P.
JNeurochem, December 2009; 111(6):1514-28. Epub 2009 Oct 14
Antibodies for the treatment
of bacterial infections: current experience and future prospects
Christopher Bebbington and Geoffrey Yarranton. December 2008,
Current Opinion in Biotechnology Vol 19, Issue 6
An
engineered human antibody Fab fragment specific for Pseudomonas aeruginosa
PcrV antigen has potent anti-bacterial activity. Baer M, Sawa T, Flynn P,
Luehrsen K, Martinez D, Wiener-Kronish JP, Yarranton G, Bebbington C.,
Infect Immun., December 2008
High-resolution
characterization of antibody fragment/antigen interactions using Biacore T100.
Papalia GA, Baer M, Luehrsen K, Nordin H, Flynn P, Myszka DG.,Anal Biochem.,
December 2006 1;359(1):112-9
Presentations
KaloBios Pharmaceuticals, Inc. at American Thoracic Society's ("ATS") International
Conference - Poster /
Presentation
Sunday, May 16, 2010
Disclaimer: The information contained in the listed publications
concerns biologics that are under pre-clinical and/or clinical
investigation and which have not yet been approved for marketing by the
U.S. Food and Drug Administration (FDA). They are currently limited by
Federal law to investigational use, and no representations are made as
to their safety or effectiveness for the purposes for which they are
being investigated.
|
